Recursion said it expects to start its first registrational trial in the second half of 2027 for REC-4881, following updated positive clinical data in oral familial adenomatous polyposis (FAP). The company tied the timing to discussions with the FDA after results were presented from the Phase Ib/II TUPELO trial (NCT05552755). Recursion reported that most patients treated with REC-4881 saw reductions in both larger, higher-risk polyps and lower GI polyp burden across the GI tract from a single oral therapy approach. The drug is described as a first-in-class allosteric inhibitor of MEK1 and MEK2, licensed globally from Takeda. The company framed the dataset as its clearest proof point to date for a pharmacologic option in a lifelong disease that has historically relied on endoscopic surveillance and prophylactic surgery.